TriSalus Life Sciences, Inc. (NasdaqGM: TLSI)
Health Care · Biotechnology · US
$5.27
0.00% today · +8.4% 1Y
TriSalus Life Sciences, Inc. (NasdaqGM: TLSI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $324.50M and employs 102 people.
Over the last twelve months the share price has gained 8.4%, trading between 2.20 and 7.95.
Tweenvest scores TriSalus Life Sciences, Inc. across four factors: quality 21/100, value 73/100, growth 100/100. Its strongest factor is growth.
TLSI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $324.50M
- Revenue (TTM)
- $45.08M
- P/E
- —
- EPS
- -1.15
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- $7.95
- 52-week low
- $2.20
- Avg volume (3M)
- —
- Shares outstanding
- 61.57M
- Employees
- 102
- Next earnings
- —
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
- Founded
- 2009
- Listed since
- Feb 8, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.